Dual-cycle signal amplification on an Au@CeO2-x/Bi2MoO6 platform: Toward an ultrasensitive and enzyme-free sandwich immunosensor for CA125 in clinical diagnostics
Biosensors and Bioelectronics · 2026
DOI: 10.1016/j.bios.2026.118511 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Biosensors and Bioelectronics, 2026. Verfasst von Minjie Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Bismuth and Rhenium Science, University of Shanghai for Science and Technology, Shanghai, 200093, China; USST-UH International Joint Lab…. Hauptthemen laut MEDLINE: CA-125 Antigen, Biosensing Techniques, Ovarian Neoplasms, Membrane Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Henan Normal University, Henan University.
Abstract (Originalsprache)
The early detection of ovarian cancer biomarkers is essential for effective diagnosis, calling for highly sensitive and reliable immunosensing platforms. In this work, we present a dual-cycle amplified sandwich-type electrochemical immunosensor for the detection of Carbohydrate Antigen 125 (CA125), a key biomarker of ovarian cancer. The sensing platform was fabricated by immobilizing the primary antibody (Ab1) on a glassy carbon electrode modified with Au@GO-Chi-Fc nanocomposite. A catalytic probe was prepared by conjugating the secondary antibody (Ab2) with gold nanoparticles anchored on Ce-doped Bi2MoO6 nanoflowers (Au@CeO2-x/Bi2MoO6). These probes efficiently catalyze the reduction of p-nitrophenol (p-NP) to p-aminophenol (p-AP), which subsequently triggers an electrocatalytic chemical (ECC) redox cycling reaction with NaBH4, leading to significant signal amplification. This enzyme-free strategy provides the immunosensor with an ultra-wide linear range (0.0005-100 U mL-1) and an ultralow detection limit (0.00049 U mL-1), enabling accurate quantification of CA125 in diverse human serum samples. Moreover, the immunosensor demonstrates high selectivity, excellent reproducibility, and stable performance over 18 days, underscoring its robustness and clinical potential for the detection of trace CA125 in complex biological matrices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Bismuth and Rhenium Science, University of Shanghai for Science and Technology, Shanghai, 200093, China; USST-UH International Joint Laboratory for Tumor Diagnosis and Energy Treatment, University of Shangh…
- Department of Laboratory Diagnosis, Changhai Hospital, Naval Medical University, Shanghai, 20043, China.
- School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, 453007, China. Electronic address: sundong2004@htu.edu.cn.
- USST-UH International Joint Laboratory for Tumor Diagnosis and Energy Treatment, University of Shanghai for Science and Technology, Shanghai, 200093, China; School of Health Science and Engineering, University of Shangh…
Förderung
- Henan Normal University
- Henan University
Zitieren
APA
Yang, M., Feng, M., Zha, L., Liu, X., Ma, Y., Huang, Y., Ouyang, R., Sun, D., Miao, Y., & Liu, B. (2026). Dual-cycle signal amplification on an Au@CeO2-x/Bi2MoO6 platform: Toward an ultrasensitive and enzyme-free sandwich immunosensor for CA125 in clinical diagnostics. Biosensors and Bioelectronics. https://doi.org/10.1016/j.bios.2026.118511
Vancouver
Yang M, Feng M, Zha L, Liu X, Ma Y, Huang Y, et al. Dual-cycle signal amplification on an Au@CeO2-x/Bi2MoO6 platform: Toward an ultrasensitive and enzyme-free sandwich immunosensor for CA125 in clinical diagnostics. Biosensors and Bioelectronics. 2026. doi:10.1016/j.bios.2026.118511
BibTeX
@article{Yang2026,
author = {Yang, Minjie and Feng, Meina and Zha, Ling and Liu, Xi and Ma, Yuanhui and Huang, Ying and Ouyang, Ruizhuo and Sun, Dong and Miao, Yuqing and Liu, Baolin},
title = {Dual-cycle signal amplification on an Au@CeO2-x/Bi2MoO6 platform: Toward an ultrasensitive and enzyme-free sandwich immunosensor for CA125 in clinical diagnostics},
journal = {Biosensors and Bioelectronics},
year = {2026},
doi = {10.1016/j.bios.2026.118511}
}
EUVIMED